RxDoctor Payments DataLook up a doctor →

Vonda Houchin, MD

Family Medicine · Harrisburg, ARNPI 1467448837

Payments from drug & device makers

$206,129in general payments, 2019–2025

Across 1,115 payments — averaging $184.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$69K
  • Bayer$44K
  • Genentech, Inc.$37K
  • Sanofi Pasteur Inc.$23K
  • Novo Nordisk AS$18K
  • AbbVie$2K
  • plus $13K from 46 others
$51,495in research payments, 2019–2025

Across 18 payments — averaging $2860.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$50K
  • Sanofi Pasteur Inc.$1K

What the payments were for

  • Food & beverage$14,96199%
  • Education$1971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$206,129 in reported general payments places this provider in the 95th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$183,493
Medicare patients
382
Services billed
9,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate55$343,454
EliquisApixaban476$200,724
JardianceEmpagliflozin233$184,744
OzempicSemaglutide124$143,883
FarxigaDapagliflozin Propanediol181$136,074
Trelegy ElliptaFluticasone/Umeclidin/Vilanter193$131,921
JanuviaSitagliptin Phosphate100$68,271
RexultiBrexpiprazole94$66,671
KerendiaFinerenone74$65,220
Breztri AerosphereBudesonide/Glycopyr/Formoterol82$61,543
MounjaroTirzepatide57$59,649
TrulicityDulaglutide33$59,517
VraylarCariprazine Hcl30$44,733
LinzessLinaclotide57$37,327
MyrbetriqMirabegron84$36,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$266$343,45455 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$1,111$217,965309 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$814$217,774292 claims
PfizerEliquis$69,379$200,724476 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$899$151,531232 claims
Novo NordiskOzempic$644$143,883124 claims
Lilly USA, LLCMounjaro, Trulicity$565$119,16690 claims
AbbVieVraylar, Linzess, Restasis$1,906$94,129106 claims
MerckJanuvia$1,567$68,271100 claims
Otsuka America Pharmaceutical, Inc.Rexulti$559$66,67194 claims
BayerKerendia$43,817$65,22074 claims
Astellas Pharma US IncMyrbetriq$751$36,03884 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Harrisburg

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →